Table 2.
Incident malignant neoplasms as well as incident carcinoma in situ in total and by tumor site during the COVID-19 pandemic (March 2020 to February 2021) compared to the pre-pandemic period (March 2019 to February 2020)
| Tumor site (ICD-10) | Pre-pandemic period: cases | Pandemic period: cases | Difference (% [95% CI])a |
|---|---|---|---|
| Malignant neoplasms | |||
| All sites (C00-C97 without C44 and C77-C79) | 42,857 | 39,980 | − 2877 (− 6.7 [− 8.7; − 4.7])* |
| Breast (C50) | 8703 | 8278 | − 425 (− 4.9 [− 9.3; − 0.2])* |
| Prostate (C61) | 6649 | 5974 | − 675 (− 10.2 [− 15.0; − 5.0])* |
| Colon (C18) | 4032 | 3568 | − 464 (− 11.5 [− 17.6; − 4.9])* |
| Lung (C34) | 3536 | 3294 | − 242 (− 6.8 [− 13.6; 0.5]) |
| Rectum (C19/C20) | 2095 | 1772 | − 323 (− 15.4 [− 23.5; − 6.5])* |
| Stomach (C16) | 1450 | 1393 | − 57 (− 3.9 [− 14.5; 8.0]) |
| Bladder (C67) | 1359 | 1347 | − 12 (− 0.9 [− 12.1; 11.8]) |
| Non-Hodgkin lymphoma (C82-C88, C96) | 1309 | 1307 | − 2 (− 0.2 [− 11.6; 12.8]) |
| Corpus uteri (C54/C55) | 1265 | 1167 | − 98 (− 7.7 [− 18.7; 4.7]) |
| Lip, oral cavity, and pharynx (C00-C14) | 1197 | 1110 | − 87 (− 7.3 [− 18.6; 5.6]) |
| Kidney (C64) | 1197 | 1092 | − 105 (− 8.8 [− 19.9; 4.0]) |
| Skin/Melanoma (C43) | 1112 | 939 | − 173 (− 15.6 [− 26.5; − 3.0])* |
| Pancreas (C25) | 999 | 1039 | 40 (4.0 [− 9.4; 19.4]) |
| Leukemia (C91-C95) | 633 | 563 | − 70 (− 11.1 [− 25.8; 6.6]) |
| Liver (C22) | 630 | 554 | − 76 (− 12.1 [− 26.7; 5.5]) |
| Esophagus (C15) | 610 | 616 | 6 (1.0 [− 15.5; 20.7]) |
| Ovary (C56) | 608 | 683 | 75 (12.3 [− 5.6; 33.7]) |
| Cervix uteri (C53) | 463 | 508 | 45 (9.7 [− 10.2; 34.1]) |
| Other | 5010 | 4,776 | − 234 (− 4.7 [− 10.5; 1.5]) |
| Carcinoma in situ | |||
| All sites (D00-D09 without D04) | 4080 | 4939 | 859 (21.1 [13.3; 29.3])* |
| Bladder (D09.0) | 1101 | 1081 | − 20 (− 1.8 [− 14.1; 12.2]) |
| Cervix uteri (D06) | 1042 | 2180 | 1,138 (109.2 [86.0; 135.3])* |
| Breast (D05) | 905 | 771 | − 134 (− 14.8 [− 26.9; − 0.7])* |
| Colon (D01.0) | 283 | 173 | − 110 (− 38.9 [− 54.8; − 17.4])* |
| Skin/Melanoma (D03) | 280 | 219 | − 61 (− 21.8 [− 41.0; 3.7]) |
| Rectum (D01.1/D01.2) | 99 | 72 | − 27 (− 27.3 [− 55.2; 17.9]) |
| Other | 370 | 443 | 73 (19.7% [− 3.9%; 49.2%]) |
ICD-10 international statistical classification of diseases and related health problems, tenth revision, CI confidence interval
*Indicates that the relative change is significantly different from zero with a significance level of 5% with Bonferroni correction (effective α error of 0.18%)
aCI with Bonferroni correction (effective CI of 99.82%)